CAP: Causes and Outcomes of Community Acquired Pneumonia
Study Details
Study Description
Brief Summary
This is a descriptive clinical research aiming:
-
To describe the clinical spectrum and clinical characteristics of community acquired pneumonia (CAP) in patients admitted to hospital
-
To identify the etiology of CAP and the antibiotic sensitivity of the isolated organisms
-
To identify the risk factors that influence the severity of CAP
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
In Vietnam, the range and relative contribution of organisms causing CAP remain unclear, largely because diagnostic tools are limited and clinical research uncommon. An improved understanding of the risk factors, etiology and clinical outcomes of CAP in Vietnam would contribute to improved approaches to patient diagnosis and clinical management. This will be achieved by following the clinical and laboratory progress and treatment outcomes of in-patients diagnosed with CAP from admission to discharge. Comparative analyses will be between subgroups including survivor and non-survivor, severe CAP and non-severe CAP, known etiology and unknown etiology, SIRS, sepsis, severe sepsis and shock septic.
Study Design
Outcome Measures
Primary Outcome Measures
- Proportion of patients who are stable at Day 3, 7 and 14 [up to 14 days]
• Criteria for clinical stability Temperature < or = 37.8oC Heart rate < or = 100 beats/min Respiratory rate < or = 24 breaths/min Systolic blood pressure > or = 90 mm Hg Arterial oxygen saturation > or = 90% or pO2 > or = 60 mm Hg on room air Ability to maintain oral intake Normal mental status
Secondary Outcome Measures
- Day 14 mortality [14 days]
Proportion of patients who die at Day 14
- Length of stay (days) [participants will be followed for the duration of hospital stay, an expected average of 2 weeks]
Length of stay from admission to discharge in days
- Need for mechanical ventilation [participants will be followed for the duration of hospital stay, an expected average of 2 weeks]
- Length of ventilation time [participants will be followed for the duration of hospital stay, an expected average of 2 weeks]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients > or = 18 years of age
-
Patient meets the criteria of pneumonia (below), established within 36h of hospitalization
-
Patient is not hospitalized or residing in a long-term-care facility within 14 days before the onset of symptoms
-
Patient has not been at a referral hospital for >2 days before admission to the study hospital
-
Informed consent to participate in the study is provided
Exclusion Criteria:
-
Severe immunosuppression as judged by the enrolling physician (e.g. HIV, leukemia, lymphoma, chemotherapy for solid tumors, long-term corticosteroid use or other immunosuppressive drugs)
-
Known active tuberculosis or current treatment for tuberculosis
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | National Hospital of Tropical Diseases | Hanoi | Vietnam | ||
| 2 | Nguyen Tri Phuong Hospital | Ho Chi Minh | Vietnam |
Sponsors and Collaborators
- Oxford University Clinical Research Unit, Vietnam
Investigators
- Principal Investigator: Kinh V Nguyen, PhD, National Hospital of Tropical Diseases
- Principal Investigator: Peter Horby, Dr., Oxford University Clinical Research Unit - Hanoi
- Principal Investigator: Rogier van Doorn, MD, Oxford University Clinical Research Unit
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 03HN